Imunon, Inc. Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares
Imunon, Inc. (IMNN) reported Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares of 5.77 million shares for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares · last filed 2023-11-14
- Imunon, Inc. stockholders' equity note, changes in capital structure, subsequent changes to number of common shares for the quarter ending 2023-09-30 was 0.00 shares.
- Imunon, Inc. stockholders' equity note, changes in capital structure, subsequent changes to number of common shares for the quarter ending 2023-06-30 was 0.00 shares.
- Imunon, Inc. stockholders' equity note, changes in capital structure, subsequent changes to number of common shares for the quarter ending 2023-03-31 was 5.77M shares, a 0.00% change year-over-year.
- Imunon, Inc. stockholders' equity note, changes in capital structure, subsequent changes to number of common shares for the quarter ending 2022-12-31 was 49.00 shares.
- Imunon, Inc. stockholders' equity note, changes in capital structure, subsequent changes to number of common shares for fiscal 2022 was 5.77M shares, a 0.00% change from fiscal 2021.
- Imunon, Inc. stockholders' equity note, changes in capital structure, subsequent changes to number of common shares for fiscal 2021 was 5.77M shares.
| Period end | Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares 3 month | Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares 6 month | Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares 9 month | Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares 12 month |
|---|---|---|---|---|
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-14 | 5.77M shares 10-Q · filed 2023-11-14 | 5.77M shares derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 5.77M shares 10-Q · filed 2023-08-10 | 5.77M shares derived: sum of 3 quarters · filed 2023-08-10 | 5.77M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 5.77M shares 10-Q · filed 2023-05-11 | 5.77M shares derived: sum of 2 quarters · filed 2023-05-11 | 5.77M shares derived: sum of 3 quarters · filed 2023-05-11 | 5.77M shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 49.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 49.00 shares derived: sum of 2 quarters · filed 2023-03-30 | 49.00 shares derived: sum of 3 quarters · filed 2023-03-30 | 5.77M shares 10-K · filed 2023-03-30 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2022-11-14 | 5.77M shares 10-Q · filed 2022-11-14 | |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 5.77M shares 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | 5.77M shares 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | 5.77M shares 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |